Physicochemical Properties of Ferumoxytol, a New Intravenous Iron Preparation
Overview
Affiliations
Background: Intravenous iron is a critical component of anaemia management. However, currently available preparations have been associated with the release of free iron, a promoter of bacterial growth and oxidative stress.
Materials And Methods: We determined the molecular weight, dialysability and capacity for free iron release of ferumoxytol, a semi-synthetic carbohydrate-coated superparamagnetic iron oxide nanoparticle. Ferumoxytol was compared with three intravenous iron preparations in clinical use: iron dextran (low molecular weight), sodium ferric gluconate and iron sucrose. Intravenous iron preparations were also incubated in rat, and pooled human sera (at concentrations of 600 microM and 42 microg mL(-1) respectively) from healthy subjects.
Results: The molecular weight of ferumoxytol was 731 kDa. The relative order of molecular weight was as follows: ferumoxytol > iron dextran > iron sucrose > sodium ferric gluconate. The least ultrafilterable iron was observed with ferumoxytol and the most with ferric gluconate. The least dialysable free iron was observed with ferumoxytol and the most with ferric gluconate. Incubation of intravenous iron preparations in rat or pooled human sera demonstrated minimal free iron release with ferumoxytol. The order of catalytic iron release as detected by the bleomycin detectable iron assay was as follows: ferumoxytol < iron dextran < iron sucrose < ferric gluconate. A similar trend was observed for the in vivo serum concentration of free iron in rats.
Conclusions: In vitro observations from these experiments suggest that ferumoxytol has a favourable profile in terms of tendency to release free iron, in comparison with currently available intravenous iron preparations.
Advances in engineering nanoparticles for magnetic particle imaging (MPI).
Velazquez-Albino A, Imhoff E, Rinaldi-Ramos C Sci Adv. 2025; 11(2):eado7356.
PMID: 39772674 PMC: 11708890. DOI: 10.1126/sciadv.ado7356.
Digigow R, Burgert M, Luechinger M, Sologubenko A, Rzepiela A, Handschin S Heliyon. 2024; 10(17):e36749.
PMID: 39281449 PMC: 11401109. DOI: 10.1016/j.heliyon.2024.e36749.
MRI Detection and Therapeutic Enhancement of Ferumoxytol Internalization in Glioblastoma Cells.
Petronek M, Teferi N, Lee C, Magnotta V, Allen B Nanomaterials (Basel). 2024; 14(2).
PMID: 38251153 PMC: 10821426. DOI: 10.3390/nano14020189.
Dasi A, Kring D, Selvaraj B, Morgan P, Gerity C, Morgan E Pediatr Radiol. 2023; 53(13):2622-2632.
PMID: 37837456 DOI: 10.1007/s00247-023-05778-4.
Iron oxide nanoparticles trigger endoplasmic reticulum damage in steatotic hepatic cells.
Uzhytchak M, Lunova M, Smolkova B, Jirsa M, Dejneka A, Lunov O Nanoscale Adv. 2023; 5(16):4250-4268.
PMID: 37560414 PMC: 10408607. DOI: 10.1039/d3na00071k.